Monument Therapeutics, spin-out de COG, accède à 1.5 million de livres sterling
23 Avril 2024
Cambridge Cognition Holdings plc
("Cambridge Cognition", la "Société" ou le "Groupe")
Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development
Cambridge Cognition Holdings plc (AIM : COG), qui développe et commercialise des solutions numériques pour évaluer la santé du cerveau, est heureux de announce that Monument Therapeutics Limited ("Monument") a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced a further £0.5 million grant funding for the development of a Schizophrenia treatment.
Monument was spun out of Cambridge Cognition in 2021, with the Company maintaining a significant shareholding. Since then, Monument has focused on the application of a unique novel drug development strategy, leveraging digital cognitive assessments to match patients with new pharmaceutical treatments.
The fundraising was led by Cambridge Angels, the UK's leading business angel network, as well as the Manchester Angels and SyndicateRoom's Access EIS. The additional funds will enable Monument to commence clinical development of MT1988, a novel fixed-dose combination drug for the treatment of cognitive impairment associated with schizophrenia which has shown substantial cognitive improvement in pre-clinical studies.
This fundraising continues to demonstrate investor support for Monument's novel approach. Cambridge Cognition did not participate in the fundraise, and its holding has consequently been reduced from 28% to 25%.
Following the successful fundraise, Monument expects the first clinical trials to begin in the coming weeks and, if successful, a Phase 2 clinical trial is expected to begin in early 2025.
Matthew Stork, PDG de Cambridge Cognition, a commenté :
"This represents a significant milestone in Monument's mission to leverage precision medicine to develop effective treatments in psychiatry and neurology. Monument has a pipeline of opportunities within the CNS space each with significant unmet medical need. We are pleased to maintain a substantial holding in the business, which provides upside for Cambridge Cognition given continued success in the future."
Dr Jenny Barnett, Chief Executive Officer of Monument Therapeutics, commented:
"We are delighted to announce this latest funding round and excited to be entering the clinic. Cognitive impairment is a debilitating symptom of schizophrenia and a major unmet medical need. We are grateful to our investors and to Innovate UK for seeing the value in our development strategy".
Enquêtes
|
Notes aux rédacteurs
À propos de Cambridge Cognition
Cambridge Cognition est une entreprise technologique qui développe des produits de santé numérique pour mieux comprendre, détecter et traiter les affections affectant la santé du cerveau. Les produits logiciels de la Société évaluent la santé cognitive des patients du monde entier afin d'améliorer les résultats des essais cliniques, d'identifier et de stratifier les patients à un stade précoce et d'améliorer l'efficacité mondiale dans les industries pharmaceutique et de la santé.
Pour plus d'informations: https://cambridgecognition.com/
About Monument Therapeutics
Monument Therapeutics is bringing stratified medicine to CNS drug development. The company uses proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds. Monument Therapeutics has a pipeline of promising drug development programmes, with the most advanced two being for cognitive impairment in schizophrenia and neuroinflammation. For further information visit www.monumenttx.com
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.